| Name | Title | Contact Details |
|---|
Freespira® is an FDA-cleared digital therapeutic proven to significantly reduce or eliminate Panic Disorder and PTSD symptoms by training users to normalize respiratory irregularities in just 28 days. Health plans, self-insured employers and the Veteran`s Administration use the company`s drug-free solution to improve quality of life, reduce medical spending and support the appropriate use of valuable healthcare resources.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body.
Based in Madison Heights, MI, we are the leading provider of ambulatory infusion pumps and associated clinical services to oncologists and their patients in the U.S. We provide state-of-the-art continuous electronic ambulatory infusion pumps, along with appropriate supplies - and expert clinical support from oncology certified OCN® Registered Nurses. In addition, we provide insurance expertise and advocacy service to our patients. More than 60% of oncology practices across all 50 states turn to InfuSystem as their full service source for cost-effective infusion pump management. We have 200+ employees earning the respect of patients and caregivers, physicians, nurses and pharmacists, case managers, billing specialists and claims administrators, by combining compassionate, evidenced-based care with knowledge, expertise and accuracy. InfuSystem is ambulatory infusion made easy.
MindClick Partners Inc is a West Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.